Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
- Trial name
- NCT04453397
- Testing
- TNB-383B
- Where
- United States
- Sponsor
- TeneoOne Inc.
Multiple Myeloma
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.
- Trial name
- NCT01145989
- Testing
- AT9283
- Where
- 6 sites in Canada
- Volunteers
- 8 people
- Sponsor
- NCIC Clinical Trials Group
Acute Leukemia, Chronic Myeloproliferative Disease
A Phase I Trial of ZIO-101 in Hematologic Cancers
This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical.
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma
- Trial name
- NCT00592046
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Multiple Myeloma
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma
This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing. This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that…
- Trial name
- MUKeleven (NCT03015922)
- Testing
- Lenalidomide or Pomalidomide, REOLYSIN
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Leeds
Myeloma Multiple
Limited-duration Teclistamab
This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of…
- Trial name
- NCT05932680
- Testing
- Off Drug Surveillance
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hematological Malignancies, Multiple Myeloma
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.
- Conditions
- Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
- Trial name
- NCT02576496
- Testing
- Tinostamustine
- Where
- 18 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Mundipharma Research Limited
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
- Trial name
- NCT04657861
- Testing
- APRIL CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Myeloma
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is a 2 part study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of DS-3032b that can be given to patients with multiple…
- Trial name
- NCT02579824
- Testing
- DS-3032b
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00635024
- Testing
- anti-thymocyte globulin, melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
This is an open label phase I/II trial to determine the safety and the biologic activity of the bendamustine, bortezomib and pegylated liposomal doxorubicin combination.
- Trial name
- NCT01177683
- Testing
- Bendamustine, Doxorubicin, Bortezomib
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sherif Farag, MB, BS
Multiple Myeloma
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.
- Trial name
- NCT00352742
- Testing
- ATN-224 + bortezomib
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Attenuon
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse
- Trial name
- NCT01435720
- Testing
- SNS01-T
- Where
- 7 sites in United States, South Africa
- Volunteers
- 15 people
- Sponsor
- Senesco Technologies, Inc.
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple…
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00047203
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with bortezomib and to see how well they work in treating patients with relapsed multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00243035
- Testing
- bortezomib, tipifarnib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of KQ-2003 CAR-T cells for the treatment of multiple myeloma
- Trial name
- NCT04714827
- Testing
- KQ-2003 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Province Cancer Hospital
Multiple Myeloma
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM)…
- Trial name
- ABE-DESCART (NCT06154902)
- Testing
- Idecabtagene vicleucel, Not treated
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Plasma Cell Myeloma
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
Primary Objectives: To determine the maximum tolerated dose of SAR650984 (isatuximab) with lenalidomide and dexamethasone (LD) in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01749969
- Testing
- isatuximab SAR650984, lenalidomide, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sanofi
Refractory Multiple Myeloma
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.
- Trial name
- NCT03589222
- Testing
- Selinexor, Daratumumab, Bortezomib
- Where
- 15 sites in Spain
- Volunteers
- 62 people
- Sponsor
- PETHEMA Foundation
Leukemia, Lymphoma
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00619645
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.